News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis International AG Painkiller Prexige Gets “Not Approvable” Letter in U.S.
September 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Sept 27 (Reuters) - U.S. regulators have rejected Novartis AG's (NOVN.VX: Quote, Profile, Research) Prexige painkiller, a move that had been expected after Australia withdrew the drug on concerns over liver side-effects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
FDA
FDA’s Top Cancer Regulator Declined CDER Directorship
November 6, 2025
·
2 min read
·
Tristan Manalac
Business
Basel Life Sciences Scene Embraces International Companies, Startups
November 6, 2025
·
6 min read
·
Angela Gabriel
Rare diseases
FDA Overruled Reviewers in Approving Stealth’s Barth Syndrome Treatment
November 5, 2025
·
2 min read
·
Dan Samorodnitsky
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie